Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Celgene Corporation



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.6%. By the end of trading, Celgene Corporation fell 80 cents (-1.1%) to $70.83 on light volume. Throughout the day, 1.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.6 million shares. The stock ranged in price between $70.42-$71.58 after having opened the day at $71.17 as compared to the previous trading day's close of $71.63. Other companies within the Drugs industry that declined today were:

MEI Pharma



), down 16.6%,

Hemispherx Biopharma



), down 10.5%,

Cadence Pharmaceuticals


Scroll to Continue

TheStreet Recommends


), down 9.9%, and

Cell Therapeutics



), down 9.2%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $31.07 billion and is part of the

health care

sector. The company has a P/E ratio of 21, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 6.5% year to date as of the close of trading on Wednesday. Currently there are 25 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Celgene Corporation as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,




), up 21.7%,

Sarepta Therapeutics



), up 14.3%,

Repros Therapeutics



), up 10.6%, and




), up 9.6%, were all gainers within the drugs industry with

Forest Laboratories



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now